The Lancelot technology delivers enhanced hemodynamics through the integration of precision laser cutting and after ...

The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, device maker JenaValve Technology announced. This approval makes Trilogy the ...

With its FDA approval, JenaValve intends to commence launch activity for the Trilogy System immediately with participating ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...

Approval marks a historic milestone for Americans living with ssAR who are at high risk for surgery and previously had no dedicated transcatheter treatment option ...

I’m a 79-year-old female. Recently, I was diagnosed with moderate calcification of leaflets on my mitral valve. I have no symptoms but heard from a recent talk that even moderate calcification could ...